Tumor Biology

, Volume 35, Issue 6, pp 5953–5963 | Cite as

MiR-203 is downregulated in laryngeal squamous cell carcinoma and can suppress proliferation and induce apoptosis of tumours

  • Linli Tian
  • Minghua Li
  • Jingchun Ge
  • Yan Guo
  • Yanan Sun
  • Ming LiuEmail author
  • Hui XiaoEmail author
Research Article


MicroRNAs (miRNAs) have been recognised to regulate cancer development and progression in carcinogenesis as either oncogenes or tumour suppressor genes. However, whether miR-203 plays a crucial role in human laryngeal squamous cell carcinoma (LSCC) remains largely unclear. In the study, we have found that miR-203 expression was significantly lower in LSCC tissues than that in corresponding adjacent non-neoplastic tissues and was negatively correlated with ASAP1 expression level. Lower expression of miR-203 was significantly related to poor differentiation, advanced clinical stages, T3–4 tumour grade, lymph node metastasis and decreased 5-year overall survival. Transfection with miR-203 inhibited proliferation, reduced invasion, induced apoptosis and caused G1 phase cell cycle arrest of Hep-2 cells in vitro, suggesting that miR-203 functioned as a tumour suppressor. We have also tested that over-expression of miR-203 may both suppress the growth of xenograft tumours in mice and downregulate the expressions of ASAP1 in vivo. Furthermore, miR-203 may regulate the expressions of mesenchymal transition (EMT) marker of E-cadherin and cancer stem cells (CSCs) marker of CD44. These findings suggest that miR-203 plays a role as a tumour suppressor in LSCC, likely by regulating ASAP1, probably in relation to EMT and CSCs and may serve as a potential target for therapeutic intervention.


Laryngeal squamous cell carcinoma miR-203 ASAP1 Proliferation Apoptosis 



The research was supported by grants from the Heilongjiang Postdoctoral Fund (LBH-Z12157), the foundation of Heilongjiang Educational Committee (12531343), the foundation of Heilongjiang Health Bureau (2012–624), the National Science Foundation of China (81241085, 81372902), the key project of Natural Science Foundation of Heilongjiang Province of China (ZD201215/H1302), the Research Fund for the Doctoral Program of Higher Education of China (20102307110007) and the Science and Technology Innovation Talent Research funds of Harbin (2012RFXXS072).

Conflicts of interest



  1. 1.
    Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin N Am. 2008;41:673–95.CrossRefGoogle Scholar
  2. 2.
    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang W, Lin P, Han C, Cai W, Zhao X, Sun B. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma. J Exp Clin Cancer Res. 2010;29:60–9.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Pillai RS, Bhattacharyya SN, Artus CG, Zoller T, Cougot N, Basyuk E, et al. Inhibition of translational initiation by Let-7 microRNA in human cells. Science. 2005;309:1573–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Ruvkun G. Clarifications on miRNA and cancer. Science. 2006;311:36–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524–9.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and non-conserved human microRNAs. Nat Genet. 2005;37:766–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–4.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch. 2008;452:1–10.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Yi R, Poy MN, Stoffel M, Fuchs E. A skin microRNA promotes differentiation by repressing ‘stemness’. Nature. 2008;452:225–9.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Lena AM, Shalom-Feuerstein R, et al. MiR-203 represses ‘stemness’ by repressing DeltaNp63. Cell Death Differ. 2008;15:1187–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.CrossRefPubMedGoogle Scholar
  14. 14.
    Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:3120–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter J, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15:6192–200.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumour-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008;68:2094–105.CrossRefPubMedGoogle Scholar
  17. 17.
    Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med. 2010;16:257–67.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Ren J, Zhu D, Liu M, Sun Y, Tian L. Downregulation of miR-21 modulates Ras expression to promote apoptosis and suppress invasion of laryngeal squamous cell carcinoma. Eur J Cancer. 2010;46:3409–16.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang T, Liu M, Wang C, Lin C, Sun Y, Jin D. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31:3859–63.PubMedGoogle Scholar
  20. 20.
    Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumour-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31:766–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–98.CrossRefPubMedGoogle Scholar
  22. 22.
    Czernilofsky AP, Levinson AD, Varmus HE, Bishop JM, Tischer E, Goodman HM. Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature. 1980;287:198–203.CrossRefPubMedGoogle Scholar
  23. 23.
    Viticchiè G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10:1121–31.CrossRefPubMedGoogle Scholar
  24. 24.
    Randazzo PA, Inoue H, Bharti S. Arf GAPs as regulators of the actin cytoskeleton. Biol Cell. 2007;99:583–600.CrossRefPubMedGoogle Scholar
  25. 25.
    Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol. 2009;11:1325–31.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Hashimoto A, Hashimoto S, Ando R, Noda K, Ogawa E, Kotani H, et al. GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS One. 2011;6(8):e23359.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Müller T, Stein U, Poletti A, Garzia L, Rothley M, Plaumann D, et al. ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients. Oncogene. 2010;29:2393–403.CrossRefPubMedGoogle Scholar
  28. 28.
    Lin D, Watahiki A, Bayani J, Zhang F, Liu L, Ling V, et al. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res. 2008;68:4352–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Sarrio D, Palacios J, Hergueta-Redondo M, Gomez-Lopez G, Cano A, Moreno-Bueno G, et al. Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer. 2009;9:74.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–58.CrossRefPubMedGoogle Scholar
  31. 31.
    Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer. 2006;94:661–71.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J. 2011;440(1):23–31.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Cheng W, Liu T, Wan X, Gao Y, Wang H. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 2012;279(11):2047–59.CrossRefPubMedGoogle Scholar
  34. 34.
    Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep. 2013;29(3):1027–36.PubMedGoogle Scholar
  35. 35.
    Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008;18:260–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated HospitalHarbin Medical UniversityHarbinChina
  2. 2.Department of Otorhinolaryngology, Head and Neck Surgery, Second Affiliated HospitalHarbin Medical UniversityHarbinChina

Personalised recommendations